

# Stefano Barco

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3649447/publications.pdf>

Version: 2024-02-01

159  
papers

6,050  
citations

134610

34  
h-index

93651

72  
g-index

166  
all docs

166  
docs citations

166  
times ranked

8235  
citing authors

#	ARTICLE	IF	CITATIONS
1	Ophthalmic complications of Lemierre syndrome. <i>Acta Ophthalmologica</i> , 2022, 100, .	0.6	6
2	Machine Learning to Predict Outcomes in Patients with Acute Pulmonary Embolism Who Prematurely Discontinued Anticoagulant Therapy. <i>Thrombosis and Haemostasis</i> , 2022, 122, 570-577.	1.8	10
3	Decline in Overall Pulmonary Embolism-Related Mortality and Increasing Prevalence of Cancer-Associated Events in the Veneto Region (Italy), 2008â€“2019. <i>Thrombosis and Haemostasis</i> , 2022, 122, 789-795.	1.8	2
4	Reduced-Dose Intravenous Thrombolysis for Acute Intermediateâ€“High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism International THrombolysis (PEITHO)-3 trial. <i>Thrombosis and Haemostasis</i> , 2022, 122, 857-866.	1.8	35
5	Clinical use and outcome of extracorporeal membrane oxygenation in patients with pulmonary embolism. <i>Resuscitation</i> , 2022, 170, 285-292.	1.3	40
6	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. <i>European Heart Journal</i> , 2022, 43, 183-189.	1.0	83
7	Splanchnic vein thrombosis-related mortality in the Veneto region (Italy), 2008â€“2019: Retrospective analysis of epidemiological data. <i>Thrombosis Research</i> , 2022, 209, 41-46.	0.8	3
8	An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and metaâ€“analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 409-421.	1.9	17
9	Current practices of standardized risk assessment for venous thromboembolism: Results from a global survey from the World Thrombosis Day steering committee. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 532-535.	1.9	7
10	Management of Lemierre Syndrome. <i>Minerva Medica</i> , 2022, 112, .	0.3	6
11	Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2022, 209, 94-98.	0.8	34
12	Trends and Risk Factors of In-Hospital Mortality of Patients with COVID-19 in Germany: Results of a Large Nationwide Inpatient Sample. <i>Viruses</i> , 2022, 14, 275.	1.5	29
13	Transient perivascular inflammation of the carotid artery (TIPIC) syndrome. <i>Vasa - European Journal of Vascular Medicine</i> , 2022, 51, 71-77.	0.6	12
14	Cardiac and Cerebral Arterial Complications of Lemierre Syndrome: Results from a Systematic Review and Individual Patient Data Meta-analysis. <i>Hamostaseologie</i> , 2022, 42, 261-267.	0.9	6
15	Definite diagnosis of plasma prekallikrein deficiency should not be based exclusively on shortening of the aPTT upon prolonged preâ€“incubation. <i>International Journal of Laboratory Hematology</i> , 2022, 44, .	0.7	2
16	Deaths related to pulmonary embolism and cardiovascular events before and during the 2020 COVID-19 pandemic: An epidemiological analysis of data from an Italian high-risk area. <i>Thrombosis Research</i> , 2022, 212, 44-50.	0.8	16
17	Tissue plasminogen activator for the treatment of adults with critical COVID-19: A pilot randomized clinical trial. <i>Thrombosis Research</i> , 2022, 216, 125-128.	0.8	10
18	Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. <i>European Heart Journal</i> , 2022, 43, 3387-3398.	1.0	69

#	ARTICLE	IF	CITATIONS
19	Major adverse limb events in patients with femoro-popliteal and below-the-knee peripheral arterial disease treated with either sirolimus-coated balloon or standard uncoated balloon angioplasty: a structured protocol summary of the "SirPAD" randomized controlled trial. <i>Trials</i> , 2022, 23, 334.	0.7	0
20	A novel management strategy for treatment of pelvic venous disorders utilizing a clinical screening score and non-invasive imaging. <i>Vasa - European Journal of Vascular Medicine</i> , 2022, 51, 182-189.	0.6	6
21	Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. <i>American Heart Journal</i> , 2022, 251, 43-53.	1.2	59
22	Anticoagulation strategies and clinical outcomes after bleeding events during anticoagulation therapy for venous thromboembolism in the practice-based Japanese registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 524-534.	1.0	1
23	Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial. <i>Lancet Haematology</i> , 2022, 9, e585-e593.	2.2	38
24	Impact of concomitant popliteal vein thrombosis in patients with acute iliofemoral deep vein thrombosis treated with endovascular early thrombus removal. <i>Vasa - European Journal of Vascular Medicine</i> , 2022, 51, 282-290.	0.6	3
25	Braided or laser-cut self-expanding nitinol stents for the common femoral vein in patients with post-thrombotic syndrome. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2021, 9, 760-769.	0.9	18
26	Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-2018: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. <i>Lancet Respiratory Medicine</i> , 2021, 9, 33-42.	5.2	100
27	c.451dupT in KLKB1 is common in Nigerians, confirming a higher prevalence of severe prekallikrein deficiency in Africans compared to Europeans. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 147-152.	1.9	7
28	Course of D-Dimer and C-Reactive Protein Levels in Survivors and Nonsurvivors with COVID-19 Pneumonia: A Retrospective Analysis of 577 Patients. <i>Thrombosis and Haemostasis</i> , 2021, 121, 098-101.	1.8	21
29	Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study. <i>Thrombosis Research</i> , 2021, 198, 135-138.	0.8	50
30	Survival and quality of life after early discharge in low-risk pulmonary embolism. <i>European Respiratory Journal</i> , 2021, 57, 2002368.	3.1	17
31	Tailoring anticoagulant treatment of patients with atrial fibrillation using a novel bleeding risk score. <i>Heart</i> , 2021, 107, 549-555.	1.2	5
32	Reader comments. <i>Baylor University Medical Center Proceedings</i> , 2021, 34, 336-336.	0.2	2
33	Acute limb ischemia in a patient with pre-fibrotic myelofibrosis complicated by heparin-induced thrombocytopenia and thrombosis " case report and systematic review of dabigatran use. <i>Vasa - European Journal of Vascular Medicine</i> , 2021, 50, 151-156.	0.6	2
34	Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 40.	1.0	79
35	Reversal of cardiopulmonary exercise intolerance in patients with post-thrombotic obstruction of the inferior vena cava. <i>Thrombosis Research</i> , 2021, 208, 219-225.	0.8	5
36	Clinical presentation and long-term follow-up of 45 patients with Mondor disease: A single-center longitudinal study. <i>Vascular Medicine</i> , 2021, 26, 409-414.	0.8	1

#	ARTICLE	IF	CITATIONS
37	COVID-19 in thrombosis research: An editorial perspective. <i>Thrombosis Research</i> , 2021, 201, 147-150.	0.8	1
38	Prevalence of pulmonary embolism in 127,945 autopsies performed in cancer patients in the United States between 2003 and 2019. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1591-1593.	1.9	5
39	Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12509.	1.0	8
40	Quality of Life 3 and 12 Months Following Acute Pulmonary Embolism. <i>Chest</i> , 2021, 159, 2428-2438.	0.4	34
41	Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: Vital registration data from 123 countries. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12520.	1.0	27
42	Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. <i>European Journal of Internal Medicine</i> , 2021, 88, 43-51.	1.0	10
43	Compromised Lung Volume and Hemostatic Abnormalities in COVID-19 Pneumonia: Results from an Observational Study on 510 Consecutive Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 2894.	1.0	2
44	Thrombosis and Dissection of the Abdominal Arteries Associated with Infarcts of Solid Organs in a Patient with COVID-19: A Novel Clinical Entity. <i>Hamostaseologie</i> , 2021, , .	0.9	4
45	The Bacteria-Associated Thrombosis, Thrombophlebitis and Lemierre syndrome (BATTLE) registry: background and rationale. <i>Hamostaseologie</i> , 2021, 41, .	0.9	0
46	Intracranial involvement and neurologic manifestations in Lemierre syndrome: analysis of 712 patients. <i>Hamostaseologie</i> , 2021, 41, .		0
47	Twelve-month clinical outcomes of a hybrid oblique self-expanding nitinol stent used for the treatment of post-thrombotic syndrome with common iliac vein compression: The TOPOS study. <i>Vascular Medicine</i> , 2021, 26, 1358863X2110176.	0.8	2
48	Sex differences in Lemierre syndrome: Individual patient-level analysis. <i>Thrombosis Research</i> , 2021, 202, 36-39.	0.8	3
49	Transient perivascular inflammation of the carotid artery (TIPIC) syndrome in a patient with COVID-19. <i>International Journal of Infectious Diseases</i> , 2021, 108, 126-128.	1.5	3
50	D-dimer testing after anticoagulant discontinuation to predict recurrent venous thromboembolism. <i>European Journal of Internal Medicine</i> , 2021, 89, 25-26.	1.0	2
51	In-hospital fatality and venous thromboembolism during the first and second COVID-19 waves at a center opting for standard-dose thromboprophylaxis. <i>Thrombosis Research</i> , 2021, 203, 82-84.	0.8	10
52	A model for estimating the health economic impact of earlier diagnosis of chronic thromboembolic pulmonary hypertension. <i>ERJ Open Research</i> , 2021, 7, 00719-2020.	1.1	14
53	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. <i>Lancet Haematology</i> , 2021, 8, e627-e636.	2.2	11
54	Efficacy and safety of a 12-week outpatient pulmonary rehabilitation program in Post-PE Syndrome. <i>Thrombosis Research</i> , 2021, 206, 66-75.	0.8	24

#	ARTICLE	IF	CITATIONS
55	Re: Internal Jugular Vein and Cerebral Venous Sinus Infective Thrombophlebitis Detected With 99mTc-HMPAO White Blood Cell Scintigraphy. <i>Clinical Nuclear Medicine</i> , 2021, 46, 858-859.	0.7	2
56	The 2019 European guidelines on pulmonary embolism illustrated with the aid of an exemplary case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytaa542.	0.3	1
57	Clinical Outcomes of Incidental Venous Thromboembolism in Cancer and Noncancer Patients: The SWISS Venous ThromboEmbolic Registry (SWITER). <i>Thrombosis and Haemostasis</i> , 2021, 121, 641-649.	1.8	8
58	In-hospital outcomes of catheter-directed thrombolysis in patients with pulmonary embolism. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 258-264.	0.4	24
59	Patients with Lemierre syndrome have a high risk of new thromboembolic complications, clinical sequelae and death: an analysis of 712 cases. <i>Journal of Internal Medicine</i> , 2021, 289, 325-339.	2.7	61
60	Management of acute pulmonary embolism: towards a (truly) global reach. <i>European Respiratory Journal</i> , 2021, 58, 2101055.	3.1	0
61	Role of age, sex, and specific provoking factors on the distal versus proximal presentation of first symptomatic deep vein thrombosis: analysis of the SWISS Venous ThromboEmbolic Registry (SWITER). <i>Internal and Emergency Medicine</i> , 2021, , 1.	1.0	2
62	Current use of catheter directed treatment of acute PE in Europe: results of survey of EAPCI and ESC Working Group on Pulmonary Circulation and Right Ventricular Function. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
63	Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial. <i>European Heart Journal</i> , 2020, 41, 509-518.	1.0	106
64	Trends in mortality related to pulmonary embolism in the European Region, 2000-2015: analysis of vital registration data from the WHO Mortality Database. <i>Lancet Respiratory Medicine</i> , 2020, 8, 277-287.	5.2	192
65	Sex-specific differences in chronic thromboembolic pulmonary hypertension. Results from the European CTEPH registry. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 151-161.	1.9	42
66	Humanitas COVID-19 Task Force Venous and Arterial Thromboembolic Complications in COVID-19 Patients Admitted to an Academic Hospital in Milan, Italy. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020, 8, 1119.	0.9	5
67	Risk stratification of normotensive pulmonary embolism: One more ride on the merry-go-round. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 256-258.	0.4	1
68	Thromboprophylaxis after renal transplantation and patient risk stratification: The case of mTOR inhibitors. <i>Thrombosis Research</i> , 2020, 195, 100-102.	0.8	1
69	Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 1251-1261.	1.0	18
70	Increased interest in acute pulmonary embolism in Italy during the COVID-19 pandemic: a google trends-based analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 52, 92-94.	1.0	4
71	Management of high-risk pulmonary embolism in an "unstable medical environment": Not only a matter of hemodynamic. <i>Thrombosis Research</i> , 2020, 195, 193-194.	0.8	2
72	The Millennial Generation of Thrombosis and Hemostasis. <i>Hamostaseologie</i> , 2020, 40, 259-261.	0.9	1

#	ARTICLE	IF	CITATIONS
73	Incidence of acute pulmonary embolism in COVID-19 patients: Systematic review and meta-analysis.. European Journal of Internal Medicine, 2020, 82, 29-37.	1.0	107
74	Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. Trials, 2020, 21, 770.	0.7	34
75	Self-Expandable Nitinol Stents for the Treatment of Nonmalignant Deep Venous Obstruction. Circulation: Cardiovascular Interventions, 2020, 13, e009673.	1.4	15
76	Lemierre syndrome: Current evidence and rationale of the Bacteria-Associated Thrombosis, Thrombophlebitis and LEmierre syndrome (BATTLE) registry. Thrombosis Research, 2020, 196, 494-499.	0.8	36
77	Anticoagulation in splanchnic and cerebral vein thrombosis: Still groping in the dark. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1080-1082.	1.0	1
78	Potential Drug Interactions between Recombinant Interleukin-2 and Direct Oral Anticoagulants: Indirect Evidence from In Vivo Animal Studies. Hamostaseologie, 2020, 40, 679-686.	0.9	1
79	Thrombosis and thromboembolism related to COVID-19: A clarion call for obtaining solid estimates from large-scale multicenter data. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 741-743.	1.0	6
80	Ambulatory treatment of low-risk pulmonary embolism in fragile patients: a subgroup analysis of the multinational Home Treatment of Pulmonary Embolism (HoT-PE) Trial. European Respiratory Journal, 2020, 56, 2000663.	3.1	8
81	The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. European Respiratory Journal, 2020, 56, 2001494.	3.1	368
82	Fatality rates and use of systemic thrombolysis in pregnant women with pulmonary embolism. ESC Heart Failure, 2020, 7, 2365-2372.	1.4	18
83	Severe plasma prekallikrein deficiency: Clinical characteristics, novel KLKB1 mutations, and estimated prevalence. Journal of Thrombosis and Haemostasis, 2020, 18, 1598-1617.	1.9	23
84	Duplex Ultrasound Investigation for the Detection of Obstructed Iliocaval Venous Stents. European Journal of Vascular and Endovascular Surgery, 2020, 60, 443-450.	0.8	15
85	Death from, with, and without pulmonary embolism. European Journal of Internal Medicine, 2020, 73, 25-26.	1.0	4
86	Venous thromboembolism in patients hospitalized for hip joint replacement surgery. Thrombosis Research, 2020, 190, 1-7.	0.8	8
87	Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale. Thrombosis Research, 2020, 190, 45-51.	0.8	44
88	Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thrombosis Research, 2020, 191, 9-14.	0.8	1,690
89	Predicting Venous Thromboembolism in Primary Care. Thrombosis and Haemostasis, 2020, 120, 531-533.	1.8	0
90	Prevalence of carotid plaque stenosis after head and neck radiotherapy – an observational study of 156 survivors. Vasa - European Journal of Vascular Medicine, 2020, 49, 467-473.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Functional outcomes and quality of life during long-term follow-up after acute pulmonary embolism: analysis of the prospective multicentre FOCUS study. <i>European Heart Journal</i> , 2020, 41, .	1.0	2
92	Reperfusion treatment for high-risk pulmonary embolism associated with COVID-19. <i>Vasa - European Journal of Vascular Medicine</i> , 2020, 49, 257-258.	0.6	0
93	Venous thromboembolism in patients hospitalized for knee joint replacement surgery. <i>Scientific Reports</i> , 2020, 10, 22440.	1.6	9
94	Illustrated State-of-the-Art Capsules of the ISTH 2019 Congress in Melbourne, Australia. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 431-497.	1.0	11
95	Incidence of Stent Thrombosis after Endovascular Treatment of Iliofemoral or Caval Veins in Patients with the Postthrombotic Syndrome. <i>Thrombosis and Haemostasis</i> , 2019, 119, 2064-2073.	1.8	31
96	Telemedicine and decentralized models of care: from anticoagulant monitoring to an expanded concept of vascular medicine. <i>Internal and Emergency Medicine</i> , 2019, 14, 1213-1215.	1.0	4
97	Optimal management of hormonal contraceptives after an episode of venous thromboembolism. <i>Thrombosis Research</i> , 2019, 181, S1-S5.	0.8	17
98	Response to "Detecting right ventricular dysfunction in patients diagnosed with low-risk pulmonary embolism: is routine computed tomographic pulmonary angiography sufficient?"™. <i>European Heart Journal</i> , 2019, 40, 3357-3358.	1.0	2
99	Optimizing the Personalized, Risk-Adjusted Management of Pulmonary Embolism: An Integrated Clinical Trial Programme. <i>Hamostaseologie</i> , 2019, 39, 117-127.	0.9	4
100	What's the Matter with Distal Deep Vein Thrombosis?. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1547-1549.	1.8	3
101	Evaluation of the predictive value of the bleeding prediction score VTE-BLEED for recurrent venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 364-371.	1.0	11
102	Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials. <i>Scientific Reports</i> , 2019, 9, 7145.	1.6	17
103	Recurrence Risk after First Symptomatic Distal versus Proximal Deep Vein Thrombosis According to Baseline Risk Factors. <i>TH Open</i> , 2019, 03, e58-e63.	0.7	15
104	Measuring functional limitations after venous thromboembolism: A call to action. <i>Thrombosis Research</i> , 2019, 178, 59-62.	0.8	36
105	Determinants of the Quality of Warfarin Control after Venous Thromboembolism and Validation of the SAME-TT2-R2 Score: An Analysis of Hokusai-VTE. <i>Thrombosis and Haemostasis</i> , 2019, 119, 675-684.	1.8	9
106	Lemierre Syndrome: Clinical Update and Protocol for a Systematic Review and Individual Patient Data Meta-analysis. <i>Hamostaseologie</i> , 2019, 39, 076-086.	0.9	30
107	Immediate and late impact of reperfusion therapies in acute pulmonary embolism. <i>European Heart Journal Supplements</i> , 2019, 21, I1-I13.	0.0	16
108	Prognostic value of right ventricular dysfunction or elevated cardiac biomarkers in patients with low-risk pulmonary embolism: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2019, 40, 902-910.	1.0	179

#	ARTICLE	IF	CITATIONS
109	Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. <i>Clinical Research in Cardiology</i> , 2019, 108, 772-778.	1.5	44
110	Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis. <i>Thrombosis Research</i> , 2019, 173, 166-171.	0.8	32
111	Anti-Factor Xa levels correlate with recurrent venous thromboembolism and clinically relevant bleeding in patients receiving low-molecular-weight heparin. , 2019, , .		0
112	Evaluation of VTE-BLEED for predicting intracranial or fatal bleeding in stable anticoagulated patients with venous thromboembolism. <i>European Respiratory Journal</i> , 2018, 51, 1800077.	3.1	14
113	Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials. <i>European Respiratory Journal</i> , 2018, 51, 1701775.	3.1	38
114	Follow-up after acute Pulmonary Embolism. <i>Hamostaseologie</i> , 2018, 38, 22-32.	0.9	36
115	Diagnosis of recurrent venous thromboembolism. <i>Thrombosis Research</i> , 2018, 163, 229-235.	0.8	14
116	Prevention of early complications and late consequences after acute pulmonary embolism: Focus on reperfusion techniques. <i>Thrombosis Research</i> , 2018, 164, 163-169.	0.8	8
117	Medical Management of Pulmonary Embolism. , 2018, , 371-387.		0
118	Determinants of diagnostic delay in chronic thromboembolic pulmonary hypertension: results from the European CTEPH Registry. <i>European Respiratory Journal</i> , 2018, 52, 1801687.	3.1	78
119	Pulmonary Embolism: Contemporary Medical Management and Future Perspectives. <i>Annals of Vascular Diseases</i> , 2018, 11, 265-276.	0.2	3
120	Sex-specific differences in the distal versus proximal presenting location of acute deep vein thrombosis. <i>Thrombosis Research</i> , 2018, 172, 74-79.	0.8	18
121	Differential impact of syncope on the prognosis of patients with acute pulmonary embolism: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2018, 39, 4186-4195.	1.0	55
122	Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 689-695.	1.0	11
123	Pulmonary embolism. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18028.	18.1	208
124	Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 404-408.	1.0	7
125	Predictive value of venous thromboembolism (VTE) + BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study. <i>British Journal of Haematology</i> , 2018, 183, 457-465.	1.2	32
126	Detection and Differential Diagnosis of Prekallikrein Deficiency: Genetic Study of New Families and Systematic Review of the Literature. <i>Blood</i> , 2018, 132, 2496-2496.	0.6	0



#	ARTICLE	IF	CITATIONS
127	Systemic Thrombolytic Therapy for Acute Pulmonary Embolism: Who Is a Candidate?. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 056-065.	0.8	17
128	Risk-adapted management of pulmonary embolism. Thrombosis Research, 2017, 151, S92-S96.	0.8	18
129	Survival and recurrent venous thromboembolism in patients with first proximal or isolated distal deep vein thrombosis and no pulmonary embolism. Journal of Thrombosis and Haemostasis, 2017, 15, 1436-1442.	1.9	53
130	Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians. Internal and Emergency Medicine, 2017, 12, 437-443.	1.0	5
131	Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow-up study. Journal of Thrombosis and Haemostasis, 2017, 15, 2176-2183.	1.9	13
132	Letter by Barco et al Regarding Article, "Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis". Stroke, 2017, 48, e266.	1.0	1
133	Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. Thrombosis Research, 2017, 160, 76-82.	0.8	13
134	Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study. Journal of Thrombosis and Haemostasis, 2017, 15, 1757-1763.	1.9	38
135	Safety of prothrombin complex concentrate in healthy subjects. British Journal of Haematology, 2017, 176, 664-666.	1.2	3
136	External validation of the VTE-BLEED score for predicting major bleeding in stable anticoagulated patients with venous thromboembolism. Thrombosis and Haemostasis, 2017, 117, 1164-1170.	1.8	71
137	Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study. Thrombosis and Haemostasis, 2017, 117, 2425-2434.	1.8	9
138	Anticoagulants for the prevention and treatment of catheter-related thrombosis in adults and children on parenteral nutrition: a systematic review and critical appraisal. Blood Transfusion, 2017, 15, 369-377.	0.3	13
139	Catheter-directed thrombolysis for acute pulmonary embolism: Where do we stand?. Lung India, 2017, 34, 221.	0.3	2
140	European Union-28: An annualised cost-of-illness model for venous thromboembolism. Thrombosis and Haemostasis, 2016, 115, 800-808.	1.8	85
141	Home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban. Thrombosis and Haemostasis, 2016, 116, 191-197.	1.8	38
142	In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. British Journal of Haematology, 2016, 172, 255-261.	1.2	48
143	Primary thromboprophylaxis for adult patients on home parenteral nutrition: A comment on the 2016 ESPEN guideline. Clinical Nutrition, 2016, 35, 1579-1580.	2.3	5
144	Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study. Journal of Thrombosis and Thrombolysis, 2016, 42, 600-609.	1.0	50

#	ARTICLE	IF	CITATIONS
145	Edoxaban for pulmonary embolism with right ventricular dysfunction. <i>Lancet Haematology</i> , 2016, 3, e405-e406.	2.2	0
146	OC-01 - Clinical history of cancer patients with isolated distal deep vein thrombosis: a multicenter cohort study. <i>Thrombosis Research</i> , 2016, 140, S168.	0.8	8
147	Home parenteral nutrition-associated thromboembolic and bleeding events: results of a cohort study of 236 individuals. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1364-1373.	1.9	21
148	Cost-of-illness model for venous thromboembolism. <i>Thrombosis Research</i> , 2016, 145, 130-132.	0.8	12
149	Management of Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2016, 67, 976-990.	1.2	258
150	In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1799-1805.	1.9	66
151	Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 836-838.	1.8	16
152	Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria phenotype in patients with splanchnic vein thrombosis. <i>Thrombosis Research</i> , 2014, 133, 1052-1055.	0.8	17
153	New oral anticoagulants in elderly patients. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 215-224.	0.7	60
154	Post-infectious acute glomerulonephritis and transient coagulation factor XIII deficiency associated with acute parvovirus B19 infection in a young woman. <i>Human Pathology</i> , 2013, 44, 1192-1193.	1.1	1
155	Pregnancy and Venous Thromboembolism. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 549-558.	1.5	81
156	Cerebral Venous Thrombosis and Thrombophilia: A Systematic Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 913-927.	1.5	64
157	Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1297-1302.	1.9	129
158	Adverse Reactions to Anaesthetics Prevented by the Use of Specific Laboratory Tests. <i>European Journal of Inflammation</i> , 2011, 9, 79-81.	0.2	5
159	Efficacy of Fondaparinux in the Treatment of Heparin-Induced Thrombocytopenia with Venous Thromboembolism: Reduction of Thromboembolic Burden, Normalization of Platelet Count and Disappearance of Anti-Platelet Factor 4/Heparin Antibodies.. <i>Blood</i> , 2006, 108, 575-575.	0.6	14